Compass Pathways receives a Buy initiation from Jefferies as analysts cite its late-stage psilocybin therapy program for treatment-resistant depression

Compass Pathways receives a Buy initiation from Jefferies based on analyst expectations that its psilocybin-assisted therapy program could create meaningful value in mental health treatment and public markets. The focus centers on the companys development pipeline, investor sentiment, and how Wall Street is positioning the stock. Psilocybin is central because Compass is advancing a regulated therapeutic model for treatment-resistant depression, a high-need indication with large commercial potential. Analyst coverage signals growing institutional attention to psychedelic medicine as a biotech category rather than a fringe sector. The broader significance lies in how financial firms evaluate psychedelic drug developers through clinical milestones, commercialization prospects, and competitive positioning. Positive initiation coverage can influence market visibility, capital access, and confidence around the emerging psychedelic therapeutics industry.